Brokers Issue Forecasts for ORIC FY2026 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($2.15) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.09.

ORIC has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Thursday, May 29th. Guggenheim reiterated a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. JPMorgan Chase & Co. increased their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Oppenheimer dropped their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $19.17.

ORIC Pharmaceuticals Trading Down 3.7%

Shares of NASDAQ:ORIC opened at $9.39 on Wednesday. The stock has a 50 day moving average of $5.94 and a 200 day moving average of $7.71. The company has a market cap of $667.52 million, a PE ratio of -5.16 and a beta of 1.49. ORIC Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in ORIC Pharmaceuticals during the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets acquired a new stake in shares of ORIC Pharmaceuticals in the fourth quarter worth approximately $71,000. Arizona State Retirement System acquired a new stake in shares of ORIC Pharmaceuticals in the first quarter worth approximately $56,000. PNC Financial Services Group Inc. boosted its stake in shares of ORIC Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock worth $109,000 after acquiring an additional 2,520 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in ORIC Pharmaceuticals during the fourth quarter worth $118,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Dominic Piscitelli sold 2,976 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $10.01, for a total value of $29,789.76. Following the completion of the transaction, the chief financial officer now directly owns 102,117 shares in the company, valued at $1,022,191.17. This trade represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 6,200 shares of company stock valued at $62,056. 6.82% of the stock is currently owned by corporate insiders.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.